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Aging is a complex organismal process that is
controlled by genetic, environmental, and behavioral
factors. Accumulating evidence supports a role for
different cell cycle inhibitors in mammalian aging.
Little is known, however, about the upstream signals
that induce their expression. Here, we explore the
role of p38MAPK by generating a dominant-negative
allele (p38AF) in which activating phosphorylation
sites Thr180 and Tyr182 are mutated. Heterozygous
p38AF mice show a marked attenuation of p38-
dependent signaling and age-induced expression
of multiple cell cycle inhibitors in different organs,
including pancreatic islets. As a result, aged p38AF/+
mice show enhanced proliferation and regeneration
of islets when compared to wild-type littermates.
We further findanage-related reduction in expression
of the p38-specific phosphatase Wip1. Wip1-defi-
cient mice demonstrate decreased islet proliferation,
while Wip1 overexpression rescues aging-related
decline in proliferation and regenerative capacity.
We propose that modulation of p38MAPK activity
may provide new avenues for treating certain age-
related degenerative diseases.
INTRODUCTION
A major aspect of mammalian aging is an age-associated
decline in functional competence of certain self-renewing cell
types, including adult stem cells, early proliferative progenitors,
andmore differentiated cell types (Molofsky et al., 2006; Krishna-
murthy et al., 2006; Janzen et al., 2006). While several molecular
pathways have been implicated in the regulation of age-related
phenotypes, recent studies have focused on the products of
the Cdkn2a tumor suppressor locus, Ink4a and Arf, that inhibit
proliferation and promote senescence. Expression of p16Ink4a
and p19Arf increases markedly with aging in several murine
tissues and is modulated by anti-aging maneuvers such as142 Developmental Cell 17, 142–149, July 21, 2009 ª2009 Elsevier Icaloric restriction (Zindy et al., 1997; Krishnamurthy et al.,
2004). More recent work with hematopoietic stem cells, neural
stem cells, and pancreatic islets has shown p16Ink4a levels not
only correlate with aging, but also contribute to age-induced
replicative failure in these tissues (Molofsky et al., 2006; Krishna-
murthy et al., 2006; Janzen et al., 2006). While p16Ink4a appears
to serve as a biomarker and effector of aging, themolecular basis
for its induction with aging is poorly understood.
The most extensively characterized regulators of p16Ink4a
expression are those that are activated in response to onco-
genes. For example, in human fibroblasts, Ras-Raf activation
results in increased p16Ink4a expression through Erk-mediated
activation of Ets1/2 transcription factors (Ohtani et al., 2001).
Additionally, a few repressors of Cdkn2a transcription have
been identified. These include the T-box proteins and the poly-
comb group (PcG) genes (Bmi1, Ezh2, Cbx7, Mel18) (Jacobs
et al., 1999; Jacobset al., 2000;Gil et al., 2004;Krancet al., 2003).
Several lines of evidence support a role for p38MAPK in the
regulation of p16Ink4a and p19Arf expression. Overexpression of
active MKK3 or MKK6, which lie upstream of p38MAPK, results
in activation of p16Ink4a transcription under certain conditions
(Wang et al., 2002). Activation of p38MAPK in cells that are defi-
cient in the p38 negative regulator, Wip1 phosphatase, also
contributes to p16Ink4a and p19Arf upregulation in some, but
not all, cell types and could explain why Wip1-deficient MEFs
exit the cell cycle prematurely (Bulavin et al., 2004). This pathway
could also be critical in renderingWip1-deficient MEFs resistant
to oncogene-induced transformation. Finally, several candidate
regulators of p16Ink4a and p19Arf expression, including Bmi1,
have been identified that p38MAPK may regulate in some
in vitro systems (Voncken et al., 2005). Whether p38MAPK
signaling modulates expression of Ink4a/Arf and other inhibitors
of cell cycle progression with aging in vivo, however, is largely
unknown.
RESULTS
No Apparent Phenotype in Mutant Mice with Attenuated
p38MAPK Signaling
To investigate the role of p38MAPK in vivo, we generated p38a
mutant mice in which we substituted Thr180 with Ala andnc.
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p38 in Islets AgingFigure 1. Activation of p38MAPK Is Required for Induction of Inhibitors of Cyclin-Dependent Kinases with Age
(A) Activation of p38 pathway was analyzed 30min after different doses of UVC treatment in MEFs obtained fromWT and p38AF/+mice. Analysis of HSP25 phos-
phorylation was used as a read out for p38MAPK activation.
(B) Activation of p38 pathway was analyzed in TNFa (10 ng/ml)-treated MEFs obtained from WT and p38AF/+ mice.
(C) Analysis of gene expression in young (2–3 months old, Y) and old (22–25 months old, O) WT and p38AF/+ mice was carried out in different organs using
RT-PCR. At least six mice for each genotype were used for analysis. *p < 0.05.Tyr182 with Phe (see Figures S1A–S1D available online). These
phosphorylation sites are essential for p38MAPK activation,
and we expectedly found that homozygous p38AF/AF mutant
embryos die around day 11.5 with placental and heart defects
(Figures S1E and S1F) similar to that observed inMkk3/6-double
mutant and p38a-deficient mice (Adams et al., 2000; Brancho
et al., 2003). As mutation of these phosphorylation sites in vitro
generates a dominant negative p38 isoform (Raingeaud et al.,
1996), we therefore investigated the p38AF allele for this possi-
bility in vivo. p38AF/+mice were intercrossed, andmouse embryo
fibroblasts (MEFs) were derived from day 10.5 embryos of three
genotypes: wild-type, p38AF/+, and p38AF/AF. The MAPK super-Devfamily consists of three major signaling pathways, Erk, Jnk,
and p38. We found that the activation of Erk and Jnk in p38AF/+
and p38AF/AF MEFs was similar to wild-type cells after treatment
with UVC and TNFa at different doses and time points (Figures
1A, 1B, and S2). In contrast, phosphorylation of the p38MAPK
downstream target Hsp25 was abrogated in p38AF/AF and
substantially reduced in p38AF/+ MEFs (Figures 1 and S2).
Thus, deregulation of p38MAPK signaling either by loss of the
upstream kinases, Mkk3 and Mkk6 (Brancho et al., 2003), or
by mutation of activating phosphorylation sites (present study),
specifically attenuates p38MAPK signaling without an effect on
other MAPK pathways. In addition, our finding confirms thatelopmental Cell 17, 142–149, July 21, 2009 ª2009 Elsevier Inc. 143
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one mutant allele sufficient to suppress p38MAPK signaling in
MEFs.
p38MAPK plays an important role in numerous cellular
processes and was proposed to be a tumor suppressor
(reviewed in Bulavin and Fornace, 2004). To understand whether
attenuation of p38MAPK in our mouse model contributes to
tumorigenesis, we analyzed p38AF/+ mice for predisposition to
spontaneous tumors. A careful examination of old mice revealed
no apparent difference between wild-type and p38AF/+ litter-
mates in formation of spontaneous tumors (data not shown).
We further crossed p38AF/+ mice with Em-myc transgenics and
APCMin mice to investigate whether p38MAPK contributes to
lymphoid and epithelial cancers, the most common types of
tumors in mice. No difference was found in the onset of B cell
lymphomas or the number of polyps between different geno-
types (Figure S3). Thus, reduction of p38 signaling as seen in
p38AF/+ mice does not contribute to spontaneous, myc- or
APCMin-induced tumorigenesis.
p38MAPK Plays a Major Role in Regulating Expression
of Multiple Cell Cycle Inhibitors
To investigate whether p38MAPK regulates p16Ink4a and p19Arf
expression with age, we next analyzed gene expression in
different organs obtained from young (2-3 months) and old
(22–25 months) wild-type and p38AF/+ littermates (Figure 1C).
Consistent with previous data (Zindy et al., 1997; Krishnamurthy
et al., 2004), quantitative PCR analysis reveals an increase in
p16Ink4a and p19Arf mRNA levels in multiple organs in wild-type
mice of advanced age. In striking contrast, p16Ink4a and p19Arf
levels remain low in old p38AF/+ mice at levels comparable to
young mice (Figure 1C, left panels). This finding suggests that
p38MAPK activity is required for full Ink4a/Arf induction with
aging in several tissues.
We next extended our analysis to two other inhibitors of cyclin-
dependent kinases, Cdkn2b (p15Ink4b) and p21Waf1. Cdkn2b is
located in close physical proximity to the Cdkn2a locus and its
expression is coordinately regulated in some settings (e.g.,
Bmi1 loss; Jacobs et al., 1999; Gonzalez et al., 2006), while
p21Waf1 is a downstream target of p19Arf-p53 signaling pathway.
The expression of these two genes is also increased in multiple
tissues harvested from old wild-type mice, although to a lesser
extent than p16Ink4a and p19Arf (Figure 1C, right panels). As
with Ink4a/Arf expression, however, p15Ink4b and p21Waf1
expression levels in old p38AF/+ mice were generally lower than
wild-type mice and instead were comparable to expression in
young mice.
p38MAPK Controls Age-Related Decline in Islet
Proliferation and Regenerative Capacity
Given that islet replication is known to decline with age in
humans (Butler et al., 2003) and mice (Teta et al., 2005; Krishna-
murthy et al., 2006) and given the large effects on gene expres-
sion we observed in isolated p38AF/+ islets (Figure 1C), we chose
to further investigate the impact of compromised p38MAPK
signaling on islet physiology and proliferation. First, we analyzed
the level of Hsp25 phosphorylation, a readout for p38MAPK
signaling. Hsp25 phosphorylation was significantly increased in
the pancreas of old wild-type mice (Figure 2A). In contrast, no144 Developmental Cell 17, 142–149, July 21, 2009 ª2009 Elsevier Indetectable change was observed in old versus young p38AF/+
mice. This observation suggests that age-related changes in
islets result in activation of p38MAPK (Figure 2A), which in turn
upregulates p16Ink4a and p19Arf (Figure 1C).
As p16Ink4a limits proliferation and regenerative capacity of
b cells and is induced with advancing age in wild-type, but not
p38AF/+ mice (Figure 1C), we tested whether decreased
p16Ink4a expression in p38AF/+ mice influenced islet physiology.
Plasma blood glucose measurements following intraperitoneal
glucose tolerance tests (IPGTT) and insulin tolerance tests (ITT)
revealed neither compromised insulin sensitivity nor evidence
for insulin resistance in p38AF/+ mice (data not shown). Further-
more, overall pancreatic morphology, islet size, shape, and
number were similar between wild-type and p38AF/+ littermates
of different age groups (data not shown). Therefore, in
unstressed animals, attenuated p38MAPK signaling did not
overtly enhance islet function, even in old mice.
To determine the effects of p38MAPK with aging, islets in
young and old wild-type and p38AF/+ littermates were analyzed.
No evidence of pancreatic neoplasia was noted in p38AF/+
animals (data not shown). Islet proliferation measured by calcu-
lating the Ki67+ proliferation index was significantly decreased
with aging in wild-type mice (Figure 2B). Attenuation of p38
signaling as in p38AF/+ mice did not affect islet proliferation in
young mice; however, the age-induced decrease in islet prolifer-
ation in 22- to 24-month-old p38AF/+ mice was partially rescued
when compared to wild-type counterparts. We believe that
incomplete rescue of islet proliferation noted in p38AF/+ mice is
most likely the result of Ink4a/Arf-independent mechanisms of
aging as was previously described for p16Ink4a-deficient mice
(Krishnamurthy et al., 2006).
To study the effect of attenuated p38MAPK signaling on islet
physiology under stressed conditions, we utilized a well-charac-
terized model of islet regeneration after treatment with strepto-
zocin (STZ). STZ is a specific b cell toxin that induces rapid
hyperglycemia, simulating type 1 diabetes, when given as
a single dose. Importantly, the ability to control islet proliferation
and glucose levels as well as the survival of STZ-treated mice
decline with advancing age and are enhanced in animals lacking
p16Ink4a (Krishnamurthy et al., 2006). We could not use mice
older than 14 months for this study due to prohibitively high
mortality rate (data not shown). Mice of different ages were
injected with STZ and glucose levels were monitored every
week for 12 weeks (Figure 2C). Blood glucose measurements
after STZ treatment were not different between young wild-
type and p38AF/+ mice (Figure 2C, top panel). However, signifi-
cant differences emerged between the two genotypes in older
mice after 11 weeks in 4- to 6 month old mice (Figure 2C, middle
panel) and after 7 weeks in 9- to 14 month old mice (Figure 2C,
bottom panel).
To understand whether the differences in glucose levels
between wild-type and p38AF/+ mice after STZ treatment were
reflective of differences in islet proliferation, we carried out
Ki67 staining in 10- to 12-month-old mice. We found that atten-
uation of p38MAPK signaling in p38AF/+mice resulted in a signif-
icant increase in islet proliferation when compared to wild-type
mice both at 3 and 30 days after STZ treatment (Figure 2D).
Taken together, these data support the conclusion that recovery
from STZ treatment, which is dependent upon p16Ink4ac.
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p38 in Islets AgingFigure 2. p38MAPK Attenuates Islet Proliferation and Regeneration with Aging
(A) Activation of p38 MAPK was analyzed in the pancreas obtained from young and old WT and p38AF/+ mice. Analysis of HSP25 phosphorylation was used as
a readout.
(B) Islet proliferation was measured by Ki67 staining, and was performed on young (2–4 months) and old (22–24 months) wild-type and p38AF/+ mice.
(C) WT and p38AF/+ mice of different age (as indicated in the panel) were treated with STZ and their blood glucose levels determined weekly. All mice that died
within 2 weeks following injection were excluded from analysis. Wild-type mice are depicted with a solid and p38AF/+ with a dashed line.
(D) Islet proliferation based on Ki67 staining was analyzed in 10- to 12-month-old wild-type and p38AF/+ mice at 3 and 30 days after STZ injection. *p < 0.05.regulation of islet proliferation (Krishnamurthy et al., 2006), is
hastened in aged p38AF/+ mice compared to their wild-type
counterparts.
Wip1 Phosphatase Is a Candidate Regulator
of p38MAPK with Aging
The mechanisms that regulate p38MAPK in old wild-type mice
(Figure 2A) are largely uncharacterized. Candidates include the
p38 phosphatases such as Wip1. As aging results in reduced
proliferation of stem cells and early progenitors (Molofsky
et al., 2006; Krishnamurthy et al., 2006; Janzen et al., 2006),Devp38-dependent regulation ofCdkn2a expression through regula-
tion of Wip1 levels is of particular interest. Wip1 is abundant in
adult stem cells, and loss of Wip1 results in increased Ink4a/
Arf expression and tumor resistance in multiple mouse models
(Bulavin et al., 2004; Shreeram et al., 2006; Demidov et al.,
2007). We therefore analyzed Wip1 expression in enzymatically
isolated islets and found a significant decrease (p < 0.05) in
Wip1 mRNA levels in islets of old versus young wild-type mice,
while the difference was insignificant in p38AF/+ mice
(Figure 3A). Because downregulation of Wip1 may contribute
to activation of p38MAPK with age, we next took advantage ofelopmental Cell 17, 142–149, July 21, 2009 ª2009 Elsevier Inc. 145
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p38 in Islets AgingFigure 3. Dose-Dependent Effect of Wip1 on Islet Proliferation and Regeneration with Aging
(A) Downregulation ofWip1mRNA levels with age inWTmice. The level ofWip1was analyzed in young (2–3months) and old (22–24months)WT and p38AF/+mice
by RT-PCR. The level of Wip1 mRNA in young wild-type mice was assumed as 1.
(B) Analysis of Cdkn2a gene expression in 4- to 6-month-old mice of different genotypes.
(C) Analysis of Ki67-positive cells in islets of 4- to 6-month-old mice of different genotypes.
(D) The level ofWip1mRNA levels in islets from young (2–3months) and aged (11–12months)WT andUbC-Wip1mice. The level ofWip1mRNA in youngwild-type
mice was assumed as 1.
(E) Islet proliferation based on Ki67 staining was analyzed in young (2–3 months) and aged (11–13 months) WT and UbC-Wip1 transgenic mice.
(F) Six- to eight-month-old WT and UbC-Wip1 mice were injected with STZ and glucose levels were monitored every week. *p < 0.05.Wip1-decifient mice to investigate Cdkn2a expression in islets.
Wip1-deficientmice display heightened p38MAPK activity (Bula-
vin et al., 2004), thus allowing us to address the question whether
forced activation of p38 is sufficient to induce Cdkn2a expres-
sion. First, we demonstrated that the level of p38 phosphoryla-
tion in Wip1-deficient islets is efficiently reduced to wild-type
levels by introducing the p38AF allele (Figure S4A). Furthermore,
Wip1 deficiency resulted in upregulation of Cdkn2a genes in
a p38MAPK-dependent manner (Figure 3B). Lastly, islet prolifer-
ation inWip1-deficient mice was reduced in a p38MAPK-depen-
dent manner (Figure 3C). We further observed impaired glucose
tolerance in Wip1-deficient mice following IPGTT (Figure S4B).
This effect was totally reversed to wild-type situation in Wip1-
deficient mice carrying the p38AF allele.
While Cdkn2a expression in islets, impaired proliferation and
glucose intolerance in Wip1-deficient mice show dependence
on p38MAPK, these effects could be indirect acting through
imposed non-physiological stress, which in turn cause b-cell
failure via p38-dependent mechanisms, such as hyperglycemia.
To rule out such a possibility, we chose to use transgenic mice in146 Developmental Cell 17, 142–149, July 21, 2009 ª2009 Elsevier Iwhich Wip1 expression is driven throughout all tissues by the
ubiquitin C (UbC) promoter (Le Guezennec et al., personal
communication). The UbC promoter allows only a mild (4-fold)
upregulation of Wip1 (Figure 3D), which falls within the normal
range of transcriptional activation of Wip1 by assorted stimuli
(Fiscella et al., 1997). In turn, this level of Wip1 overexpression
was sufficient to abolish age-induced activation of p16Ink4a and
p19Arf in islets (data not shown). We next examined whether an
increase inWip1 levelswouldbesufficient tomodulate islet prolif-
eration with aging. Young (2–3 months old) and aged (11–13
months old) wild-type and UbC-Wip1 littermates were sacrificed
and analyzed for islet proliferation based on Ki67 staining. While
we observed 3-fold drop in proliferation of wild-type FVB/N
mice between 2 and 12months,UbC-Wip1 FVB/Nmice retained
their high proliferative potential (Figure 3E). Thus, overexpression
of Wip1 is sufficient to overcome the age-related decline in islet
proliferation.
We next analyzed the regenerative capacity of islets under
conditions of Wip1 overexpression. As young p16Ink4a-deficient
and p38AF/+ mice do not show any attenuation in STZ responsenc.
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ments we used only 6- to 10-month-old mice.Mice were injected
with STZ, and their survival, weight, and glucose levels were
monitored every week for 14weeks (Figures 3F and S5). As these
mice were maintained in a pure FVB/N background, we
observed a significant difference (p = 0.042) in the survival and
a consistent change in the weight of injected wild-type and
UbC-Wip1 mice (Figure S5). Significant differences in glucose
levels also emerged between the two genotypes after 11 weeks
(Figure 3F), supporting the idea that Wip1 overexpression is
sufficient to reduce age-related decline in regenerative capacity
of islets. Taken together, our genetic data suggest that modula-
tion of Wip1 levels (Figure 3) is sufficient to regulate islet prolifer-
ation and their regenerative capacity with advancing age.
Bmi1 Binding to the Ink4a Promoter Is Regulated
in a p38-Dependent Manner with Aging
Several candidate regulators of p16Ink4a and p19Arf expression
have been identified and some of them, including Bmi1, have
been found to be regulated by p38MAPK in some in vitro
systems. It has been shown that MK3, a downstream target of
p38, can directly phosphorylate Bmi1 and reduce its abundance
on chromatin (Voncken et al., 2005), a finding that we have repro-
duced in vitro (Figure S6). To directly assess the Ink4a promoter
occupancy by Bmi1 with aging, we next carried out a modified
chromatin immunoprecipitation (ChIP) assay. We could not
perform ChIP on islets due to insufficient amount of material;
therefore, we used spleen as an alternative since it shows
a similar p38-dependent upregulation of cell cycle inhibitors
with aging (Figure 1C). While we did not see a significant differ-
ence in Bmi1 mRNA levels between different genotypes of
different age, we found that Bmi1 abundance on the Ink4a
promoter was reduced 5-fold in splenocytes obtained from
old when compared to young wild-type mice. In turn, there
was only an 2.5-fold decrease for age-matched p38AF/+ mice
(Figure 4). Thus, Bmi1 binding to the Ink4a promoter is regulated
in a p38-dependent manner with aging.
DISCUSSION
To investigate the role of p38a MAPK in vivo, we established
a new mouse genetic model in which activating phosphorylation
sites Thr180 and Tyr182 were mutated to alanine and phenylal-
anine, respectively. Embryos homozygous for the manipulated
p38AF allele die during mid-gestation due to placental and heart
defects (Figures S1E and S1F) similar to p38 knockout mice
(Adams et al., 2000; Tamura et al., 2000). In accordance with
previously published data using p38 null and Mkk3/6-double
null MEFs (Bulavin et al., 2002; Brancho et al., 2003), p38AF/AF
MEFs grew into large tumors when explanted into nude mice
(data not shown). These results are consistent with the role of
p38 as a negative regulator of tumorigenesis (Bulavin et al.,
2002; Brancho et al., 2003). However, partial inactivation of
p38, as seen in p38AF/+ cells, did not result in accelerated tumor-
igenesis, and p38AF/+ mice crossed into two tumor-prone
genetic backgrounds show tumorigenic potential comparable
to wild-type (Figure S3). In turn, partial inactivation of
p38MAPK is sufficient to prevent aging-induced activation of
multiple cell cycle inhibitors, including Cdkn2a (Figure 1C), andDeveimproves proliferation and regeneration in the islets of old
p38AF/+ mice (Figures 2B and 2D).
Cdkn2a genes play a major role in regulating the decline in
proliferation and regenerative capacity in certain organs as they
age (Molofsky et al., 2006; Krishnamurthy et al., 2006; Janzen
et al., 2006) and, consequently, are major tumor suppressors
(Sherr, 2001). Attenuation of Cdkn2a expression (by either gene
knockout or by overexpression of the negative regulator Bmi1)
ameliorates the effects of aging, but may also serve as
a double-edged sword by enhancing tumorigenesis. Our data
provide important insight into the level at which activation of
Cdkn2a genes can be disrupted in order to improve age-induced
phenotypes without promoting tumorigenesis. In this respect,
partial inactivation of p38 is sufficient to reduce aging-dependent
activation of cell cycle inhibitors p16Ink4a, p19Arf, p15Ink4b, and
p21Waf1 in multiple tissues without increasing cancer predisposi-
tion (Figures 1C and S3).
p38MAPK has been implicated in the upstream regulation of
Cdkn2a expression in vitro through several signaling pathways
that either directly or indirectly modulate p16Ink4a and p19Arf
expression. A recently identified link between p38MAPK and
Bmi1 (Voncken et al., 2005) is of particular interest as Bmi1 has
been shown to regulate stem cell behavior in part through its
ability to modulate Cdkn2a expression (Molofsky et al., 2003).
It has been shown that MK3, a downstream target of p38, can
directly phosphorylate Bmi1 and reduce its abundance on chro-
matin (Voncken et al., 2005), a finding that we have reproduced
both in vitro and in vivo (Figures S6 and 4). Given this connection,
we favor a p38-Bmi1 link in the regulation of Cdkn2a expression
in aging tissues.
The mechanism of p38MAPK activation with advanced age
remains unclear (Figure 2A). Here, we show that it coincides
with downregulation of a potent regulator of p38,Wip1 phospha-
tase (Figure 3A). Wip1 deficiency results in a p38-dependent
upregulation of Cdkn2a genes and impairs islet proliferation
(Figure 3B,C). In turn, Wip1 overexpression averts the age-
related decline in proliferation and regenerative potential of islets
Young Old
Figure 4. p38-Dependent Regulation of Bmi1 Binding to the Ink4a
Promoter with Aging
Analysis of Bmi1 binding to the Ink4a promoter was analyzed by ChIP in sple-
nocytes obtained from young (2–3 months old) and old (22–25 months old) WT
and p38AF/+ mice. At least six mice for each genotype were used for analysis.
*p < 0.05.lopmental Cell 17, 142–149, July 21, 2009 ª2009 Elsevier Inc. 147
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regulator of p38 signaling with aging.
In summary, we propose that in a situation when a premature
aging phenotype or any aging-related degenerative condition is
dependent upon p38MAPK, attenuation of its signaling could be
beneficial in ameliorating such conditions. As this can be accom-
plished pharmacologically through the use of small molecule
inhibitors of p38 kinase activity now entering human clinical
trials, our genetic data suggest an approach to attenuate some
aspects of mammalian aging.
EXPERIMENTAL PROCEDURES
Targeted Mutation of p38MAPK in ES Cells
The original BAC clone RP23-83F4 of Mus musculus strain C57BL6/J (NCI
Intramural Sequencing center) was used to generate all targeting vectors. Tar-
geting vectors were constructed that contained the equivalent of 4.5 kb of
mouse DNA with an exon containing the Thr180/Tyr182 sites of p38 alpha.
These sites were subsequently mutated to alanine and phenylalanine by
site-directed mutagenesis. An additional BamH1 site was incorporated
500 bp outside the Thr180/Tyr182 sites. A PGK-neo cassette (in either of
two orientations) flanked by two LoxP sites was inserted into Nco1 site. The
entire vector was placed into pTK plasmid, which contained two flanking
thymidine kinase genes. The two targeting vectors were electroporated into
B6 ES cells (kindly provided by Dr. Colin Stewart [NIH, Frederick]). For geno-
typing by genomic Southern-blot analysis, we probed BamH1-digested DNA
with a 500 bp fragment corresponding to a region in genomic DNA immediately
50 to that in the targeting vector. Southern blot analysis of ES cell clones yielded
an approximately 9 kb hybridizing fragment corresponding to the endogenous
p38, whereas the mutated AF allele was seen as 5.9kb hybridizing band.
Statistical Analysis
To assess the statistical significance of the results, each experiment was
repeated at least three times, means and standard deviations between
different groups were calculated, and error bars were included where neces-
sary. Student’s t test was performed for paired analysis. Kaplan-Meier analysis
of survival was performed with the assistance of PRISM4 statistical analysis
software.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and six
figures and can be found with this article online at http://www.cell.com/
developmental-cell/supplemental/S1534-5807(09)00211-1.
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